Home > Neurology > The PRISM project: focusing on biological parameters across neuropsychiatric disorders

The PRISM project: focusing on biological parameters across neuropsychiatric disorders

Presented By
Dr Hugh Marston, Eli Lilly and Company Ltd, Germany
Conference
ECNP 2020
PRISM is a multidisciplinary consortium focusing on schizophrenia, Alzheimer’s disease, and major depression, as these disorders share –to some extent– symptomatologies. Renowned researchers in neuroscience, psychiatry, and neurology from various research institutions, pharmaceutical companies, and enterprises are working closely together to develop a research programme on biological parameters for these neuropsychiatric conditions [1,2]. Dr Hugh Marston (Eli Lilly and Company Ltd, Germany) explained that the PRISM project aims to develop a quantitative biological approach to the understanding and classification of neuropsychiatric diseases [1]. “Hopefully, this will lead to the revitalisation of the discovery and development of more effective treatments, as this has slowed down tremendously over the last decades. The weak link between clinical classification and biological causation is partly to blame,” Dr Marston said. Represented...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on